💨 Abstract

A new AI test can identify men with high-risk prostate cancer who would benefit from abiraterone, a drug that extends life by inhibiting testosterone production in tumors. The AI analyzes tumor samples to detect features invisible to the human eye, determining who needs the drug. Trials showed that 25% of high-risk patients could benefit, potentially saving the NHS money. Giles Turner, a patient, highlights the drug's cost and advocates for its free availability in England.

Courtesy: Jasper King